Table 4. Mean baseline and 6 month values and the mean absolute changes in lipid profile, cytokines, adiponectin and osteocalcin in the treatment and placebo group.
| Mean Change | P value* | |||||
| Baseline | 6 months | (95% CI) | Time | Treatment | Interaction | |
| Total cholesterol, mmol/L † | ||||||
| Treatment (n = 32) | 5.16 (1.19) | 5.10 (1.36) | −0.06 (−0.39, 0.28) | 0.80 (0.01) | 0.21 (0.45) | 0.42 (0.11) |
| Placebo (n = 42) | 5.11 (0.99) | 4.69 (1.06) | −0.42 (−0.65, −0.19) | |||
| Triglycerides, mmol/L † | ||||||
| Treatment (n = 32) | 1.56 (0.96) | 1.62 (0.93) | 0.06 (−0.20, 0.33) | 0.47 (0.36) | 0.24 (0.92) | 0.32 (0.09) |
| Placebo (n = 42) | 1.57 (0.72) | 1.41 (0.67) | −0.16 (−0.33, 0.01) | |||
| HDL-cholesterol, mmol/L | ||||||
| Treatment (n = 32) | 1.28 (0.29) | 1.27 (0.33) | −0.01 (−0.07, 0.05) | 0.91 (0.98) | 0.81 (0.75) | 0.47 (0.61) |
| Placebo (n = 42) | 1.29 (0.33) | 1.31 (0.41) | 0.02 (−0.06, 0.09) | |||
| LDL-cholesterol, mmol/L | ||||||
| Treatment (n = 32) | 3.17 (0.99) | 3.11 (1.19) | −0.06 (−0.34, 0.23) | 0.68 (0.01) | 0.26 (0.35) | 0.29 (0.36) |
| Placebo (n = 42) | 3.10 (0.93) | 2.76 (0.91) | −0.34 (−0.53, −0.17) | |||
| Hs-CRP, mg/L † | ||||||
| Treatment (n = 34) | 5.52 (10.82) | 3.62 (5.68) | −1.90 (−5.14, 1.34) | 0.97 (0.54) | 0.07 (0.10) | 0.80 (0.51) |
| Placebo (n = 45) | 2.44 (2.15) ‡ | 2.57 (2.66) | 0.13 (−0.31, 0.57) | |||
| TNF-α, pg/mL † | ||||||
| Treatment (n = 34) | 6.31 (2.18) | 6.60 (1.43) | 0.29 (−0.28, 0.87) | 0.82 (0.02) | 0.56 (0.29) | 0.39 (0.83) |
| Placebo (n = 45) | 6.70 (2.43) | 7.10 (2.27) | 0.40 (−0.17, 0.97) | |||
| IL-6, pg/mL § | ||||||
| Treatment (n = 34) | 1.2 (1.2, 2.1) | 1.3 (1.2, 1.8) | 0.0 (−0.4, 0.1) | NA | 0.44 (0.42) | NA |
| Placebo (n = 45) | 1.8 (1.4, 2.4) ‡ | 1.9 (1.4, 2.8) | 0.0 (−0.4, 0.5) | |||
| Total adiponectin, ng/mL † | ||||||
| Treatment (n = 34) | 6070 (3613) | 6197 (3954) | 127 (−407, 662) | 0.59 (0.95) | 0.94 (0.99) | 0.34 (0.52) |
| Placebo (n = 45) | 6424 (4408) | 6333 (4385) | −91 (−665, 484) | |||
| Total osteocalcin, ng/mL | ||||||
| Treatment (n = 34) | 17.5 (6.3) | 16.7 (7.7) | −0.8 (−2.3, 0.8) | 0.59 (0.15) | 0.43 (0.10) | 0.58 (0.92) |
| Placebo (n = 45) | 20.1 (7.8) | 19.4 (8.1) | −0.7 (−2.0, 0.6) | |||
| Undercarboxylated osteocalcin, ng/mL | ||||||
| Treatment (n = 34) | 11.3 (4.0) | 11.0 (4.5) | −0.3 (−1.4, 0.8) | 0.70 (0.45) | 0.44 (0.10) | 0.57 (0.94) |
| Placebo (n = 45) | 13.1 (5.0) | 12.9 (5.3) | −0.2 (−1.1, 0.6) | |||
Baseline and 6 month data are presented as mean (SD).
*A multivariate 2-factor repeated-measures regression analysis was used to assess time effects and time by treatment effect interactions on all outcome variables after adjustment for the variables that were different between treatment groups at baseline. Numbers in brackets represent unadjusted P values.
ogarithmically-transformed variables.
P<0.1 for the difference between groups at baseline (unpaired t test or Wilcoxon, as appropriate).
Variables not respecting normality even after transformation are presented as median (25th, 75th percentile) and an ANOVA on rank was used to assess treatment effects (adjusted for variables that were different between treatment groups at baseline).
hs-CRP, high sensitive C-reactive protein; IL-6, interleukin-6; NA, not applicable; TNF-α, tumor necrosis factor-alpha.